GMP Certified Cefepime Hydrochloride for Injection

• Application: Surgery
• Usage Mode: Injection
• Suitable for: Elderly, Children, Adult
• State: Solid
• Shape: Powder
• Type: Biological Products
• Model NO.: CHI
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: Available
• Drug Ad Approval No.: Available
• OEM: Available
• GMP: Available
• Transport Package: Vial + Box
• Specification: 0.5g, 1g
• Trademark: Fraken
• Origin: China
• HS Code: 3003201900
• Production Capacity: 100000000vials Per Month

Product Description

Cefepime Hydrochloride For Injection
Cefepime for injection, USP is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. Cefepime hydrochloride is a white to pale yellow powder. Cefepime hydrochloride contains the equivalent of not less than 825 mcg and not more than 911 mcg of cefepime (C19H24N6O5S2) per mg, calculated on an anhydrous basis. It is highly soluble in water. Cefepime for injection, USP is supplied for intramuscular or intravenous administration in strengths equivalent to 1 g, and 2 g of cefepime. Cefepime for injection, USP is a sterile, dry mixture of cefepime hydrochloride and L-arginine. It contains the equivalent of not less than 90 percent and not more than 115 percent of the labeled amount of cefepime (C19H24N6O5S2).

Indication:
Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

1	Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiellapneumoniae, or Enterobacter species.
2	Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients.
3	Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiellapneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiellapneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
4	Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
5	Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiellapneumoniae, Enterobacterspecies, or Bacteroidesfragilis.

Product list:

Cefradine for Injection	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Cefazolin Sodium for Injection	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Cefoperazone Sodium and Sulbactam Sodium for Inj.	1.0g/1.5g/2.0g	1/10/50vial/box,600/1000vial/carton	USP
Cefoperazone Sodium for Inj.	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Ceftriaxone Sodium for Injection	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Cefotaxime Sodium for Injection	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Ceftazidime for Injection	0.25g/0.5g/1.0g	1/10/50vial/box,600/1000vial/carton	USP
Cefepime for injection	0.5g/1g	1/10/50vial/box,600/1000vial/carton	USP
Cefalotin Sodium for Inj	0.5g/1g	1/10/50vial/box,600/1000vial/carton	USP
Cefuroxime for injection	0.75g/1.5g	1/10/50vial/box,600/1000vial/carton	USP